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Abstract
The non-b endocrine cells in pancreatic islets play an essential counterpart and regulatory role to the insulin-producing b-
cells in the regulation of blood-glucose homeostasis. While significant progress has been made towards the understanding
of b-cell regeneration in adults, very little is known about the regeneration of the non-b endocrine cells such as glucagon-
producing a-cells and somatostatin producing d-cells. Previous studies have noted the increase of a-cell composition in
diabetes patients and in animal models. It is thus our hypothesis that non-b-cells such as a-cells and d-cells in adults can
regenerate, and that the regeneration accelerates in diabetic conditions. To test this hypothesis, we examined islet cell
composition in a streptozotocin (STZ)-induced diabetes mouse model in detail. Our data showed the number of a-cells in
each islet increased following STZ-mediated b-cell destruction, peaked at Day 6, which was about 3 times that of normal
islets. In addition, we found d-cell numbers doubled by Day 6 following STZ treatment. These data suggest a- and d-cell
regeneration occurred rapidly following a single diabetes-inducing dose of STZ in mice. Using in vivo BrdU labeling
techniques, we demonstrated a- and d-cell regeneration involved cell proliferation. Co-staining of the islets with the
proliferating cell marker Ki67 showed a- and d-cells could replicate, suggesting self-duplication played a role in their
regeneration. Furthermore, Pdx1
+/Insulin
2 cells were detected following STZ treatment, indicating the involvement of
endocrine progenitor cells in the regeneration of these non-b cells. This is further confirmed by the detection of Pdx1
+/
glucagon
+ cells and Pdx1
+/somatostatin
+ cells following STZ treatment. Taken together, our study demonstrated adult a-
and d-cells could regenerate, and both self-duplication and regeneration from endocrine precursor cells were involved in
their regeneration.
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Introduction
The islets of Langerhans within the pancreas play a pivotal
role in maintaining glucose homeostasis. Each islet typically
contains five endocrine cell types, which include glucagon-
producing a-cells, insulin-producing b-cells, somatostatin-produc-
ing d-cells, pancreatic polypeptide-producing PP-cells, and
ghrelin-producing e-cells. The prevailing model of embryonic
endocrine cell development is that all islet cells arise from
common precursors, and sequential activation of hormone-
specific genes are the key to their differentiation [1,2,3].
Although the reports on the precise appearance of the different
lineages vary, it is generally found that most of the hormone-
expressing cells that comprise the islets rapidly emerge around
E13.5–E15.5 in mice [4,5,6], a period often referred to as the
secondary transition in pancreatic development [1]. During
neonatal life, endocrine pancreas undergoes substantial remod-
eling, which involves significant apoptosis, replication, and
neogenesis of islet cells [7,8,9]. Islet mass grows into adulthood
to match increased hormonal demand. In contrast, there is little
change in islet mass in adults except in response to physiological/
pathological changes such as pregnancy and obesity [10,11],
while adaptive islet cell proliferation is severely restricted in aged
mice [12].
The etiology of Diabetes Mellitus is believed to be mainly
caused by the lack of b-cells (Type 1 Diabetes) or deficiency in
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theless, the non-b endocrine cells, especially the glucagon-
producing a-cells, play a major counterpart and/or regulatory
role to b-cells, thus are also crucial in the regulation of blood
glucose. For instance, a-cells and b-cells have opposing effects in
regulating blood glucose: glucagon activates glycogenolysis,
ketogenesis and gluconeogenesis in the liver thus increasing
blood glucose, while insulin stimulates the storage of glucose as
glycogen in the liver and skeletal muscle and as triacylglycerol in
adipose tissue thus reducing blood glucose. In addition, there is
tight paracrine regulation between insulin and glucagon secre-
tion: an increase in insulin suppresses glucagon secretion, and a
decrease increases it, and vice versa [13,14,15]. The balance of
the two opposing hormones is thus essential in maintaining blood
glucose homeostasis. Additional paracrine regulation among the
pancreatic endocrine hormones is also apparent. For example,
somatostatin is a potent inhibitor of glucagon and insulin
secretion [16,17,18]. Therefore, the topography of islets is
essential in the coordinated responses of b- and non b-cells to
minor changes in blood glucose, and its disruption results in the
perturbation of glycemic control.
Regeneration of adult b-cells has attracted tremendous interest
due to its potential therapeutic value for Type 1 Diabetes.
Recently, scientists have found direct supporting evidence for
adult b-cell regeneration, and begun to elucidate its mechanisms.
Interestingly, the terminally differentiated b-cells in adults have
been shown to be able to replicate/self-duplicate [19,20,21]. In
fact, self-duplication appears to be the major mechanism for b-
cell replenishment under normal physiological conditions. In
addition, it has been demonstrated that b-cells can regenerate
from stem cells located in pancreatic ducts or from progenitor
cells residing inside murine islets [22,23]. Moreover, following
extreme b-cell loss, new b-cells can be transdifferentiated from
glucagon-producing a-cells [24,25]. In summary, b-cell regener-
ation in adults can occur by self-duplication, regeneration from
progenitor cells or trans-differentiation from other cells in
mammalian systems.
Regeneration of non-b endocrine cells in adults largely remains
undefined. Previous studies have noted that the composition of a-
cells increases in the pancreatic islets of diabetic patients and
animal models [24,26,27,28,29,30], implicating the regeneration
of a-cells in adult animals and human patients as offsetting b-cell
loss. For instance, glucagon
+ cells were observed in pancreatic
interlobular ducts of diabetic NOD mice, suggesting neogenesis of
a-cells in these mice [27]. Alpha cell expansion has also been
noted in adult mice whose b-cells were destroyed by specific toxins
[24,26], and in some type 2 diabetic patients and animal models
[28,29,30]. The mechanisms or cellular origins of a-cell regener-
ation, however, remain to be investigated. Regeneration of other
non-b cells such as d-cells in adults is similarly not defined.
Our current study was aimed at exploring the regeneration of
non-b endocrine cells in adult rodents. Based on previous
observations, we hypothesized that adult non-b-cells could
regenerate, and the regeneration could accelerate in the event
of b-cell destruction. To test this hypothesis, we examined the b-
and non-b cell composition in the islets of a commonly used
diabetes animal model established with the b-cell specific toxin
streptozotocin (STZ). Our data supported regeneration of a- and
d-cells in adults. Therefore, we further explored the potential
mechanisms of their regeneration.
Materials and Methods
Ethics Statement
All animal procedures followed the guidelines set by the
Institutional Animal Care and Use Committee at both the
University of Alabama at Birmingham and Tulane University.
The animal protocol approval numbers are 100308682 and
4254, respectively.
Antibodies
Guinea pig anti-human Insulin polyclonal antibody (1:100),
mouse anti-BrdU monoclonal antibody (1:500), rabbit anti-
Glucagon (1:200), rabbit anti-Somatostatin (1:200), and rabbit
anti-PPP (1:300) polyclonal antibodies were purchased from
Millipore Corp. (Billerica, Massachusetts). Mouse anti-glucagon
monoclonal antibody (1:500) was obtained from Sigma-Aldrich
Corp. (St. Louis, MO), and a second rabbit anti-glucagon
polyclonal antibody (1:100) was obtained from Cell Signaling
Technology (Danvers, Massachusetts). Rabbit anti-Ki67 (1:500)
and rabbit anti-Pdx1 (1:500) polyclonal antibodies were pur-
chased from Abcam Inc (Cambridge, Massachusetts). Rat anti-
BrdU monoclonal antibody was obtained from AbD Serotec
(Oxford, UK), and rat anti-somatostatin monoclonal antibody
from Life Span Biosciences (Seattle, Washington). The Texas-
Red (TR), FITC and CMCA-conjugated secondary antibodies,
which include anti-mouse, anti-guinea pig, anti-rabbit, and anti-
rat antibodies, were purchased from Jackson ImmunoResearch
Laboratories Inc (West Grove, Pennsylvania). The nuclear dye
Hoechst 33342 was obtained from Sigma-Aldrich Corp. (St.
Louis, Missouri), and used at a final concentration of 2 mg/ml.
Animals and treatment
C57BL/6 mice from either Jackson Labs (Chicago, Illinois) or
Frederick Cancer Research (Hartford, Connecticut) were used in
this study. To establish the STZ-induced diabetes state, 8–10
weeks old mice were fasted overnight, and treated with freshly
prepared STZ solution at a dose of 130 mg/kg bodyweight via
intraperitoneal (i.p.) injection. Four hours after injection, the
mice received 200 ml of 20% glucose via intra-peritoneal
injection to prevent hypoglycemia caused by sudden release of
large amounts of insulin into the blood stream due to STZ-
induced b-cell destruction. Normal mice that were not injected
with STZ were used as the control. The blood glucose levels of
each mouse were measured daily following 4–6 hours of fasting
by the AlphaTRAK Blood Glucose Monitoring System (Abbott
Laboratories, Abbott Park, Illinois). For BrdU incorporation,
immediately following STZ injection, 1 mg/ml BrdU was added
into the mice’s drinking water and maintained until the mice
were sacrificed. The mice were sacrificed at different time points
post STZ injection, their pancreases harvested and processed for
histological analysis. 8–10 mice were examined for each time
point.
Immunohistochemistry
The mouse pancreases were fixed in 10% buffered formalin
solution overnight at room temperature, and then processed for
paraffin embedding and sectioning. For immunohistochemistry
assays, the pancreas sections were first deparaffinized with
sequential incubation in xylene (462 minutes), 100% ethanol
(261 minute), 95% ethanol (30 seconds), 70% ethanol (45 sec-
onds) and deionized water (1 minute). Antigen retrieval was
required for staining involving anti-BrdU, anti-Pdx1, and anti-
Ki67 antibodies. This was conducted by boiling the pancreas
slices in citrate buffer (pH 6.0) for 10–30 minutes, followed by
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water. Prior to antibody incubation, the tissue slices were
permeablized with 0.25% Triton X-100 in Phosphate-Buffered
Saline (PBS) for 30 minutes, and blocked in blocking solution
(2% Glycine, 2% Bovine Serum Albumin, 5% Fetal Bovine
Serum (FBS), 50 mM NH4Cl in PBS), for 1 hour, at room
temperature. The slices were then incubated with the primary
antibody diluted in 3% FBS in PBS, overnight at 4uC (for
antigen retrieved samples) or for 2 hours at room temperature,
followed by incubation with the corresponding secondary
antibody that were conjugated to various fluorescent agents.
For nuclear staining, Hoechst 33342 (2 mg/ml in PBS) was added
to the slides after secondary antibody incubation, and incubated,
for 10 minutes, at room temperature. The slices were then
washed in PBS and water, air-dried, mounted with glass
coverslip, and processed for fluorescence microscopy. Images
were taken with CoolSNAP-HQ digital camera (Roper Scientific,
Inc., Tucson, Arizona) that was attached to a Nikon Eclipse
Figure 1. STZ-mediated b-cell destruction. Adult C57BL/6 mice were treated with STZ at a dose of 130 mg/kg body weight via i.p. injection,
monitored for the development of hyperglycemia, and sacrificed at multiple time points post-STZ. Shown here are representative data. A: Anti-Insulin
staining of the mouse pancreases showing b-cell loss following STZ treatment. B: Quantitative distribution of b-cells in each islet section. The number
of b-cells in each islet was counted and plotted. Each circle represents one islet. For each group (normal, and 2, 4, 6, 8, and 10 days post-STZ), 26–33
representative islets from 4–5 mice were counted. The red line marks the mean value for each group. C: the statistical summary of b-cell distribution
in islets from normal mice and STZ-treated mice. D: Blood glucose levels of the mice at different day post-STZ. Note: the blood glucose levels during
the first 2 days were not included because STZ-induced hypoglycemia at early hours requiring a glucose injection to overcome hypoglycemia (see
methods). E: Serum insulin concentrations in normal mice and those treated with STZ.
doi:10.1371/journal.pone.0036675.g001
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York). Metamorph V7.7 software was used to collect images, and
Adobe photoshop to edit and analyze the microscopic data.
Quantitative determination of insulin and glucagon in
mouse serum
Blood was collected at the time of pancreas harvest following 4–
6 hours of fasting, allowed to clot at room temperature for 30 min,
and then centrifuged at 3000 rpm for 15 minutes. Serum was
transferred into new tubes, and stored at 220uC until further
analysis. The insulin and glucagon concentrations in the mouse
serum were determined using ultrasensitive ELISA kits for mouse
insulin (cat# 80-INSMSU-E01) and glucagon (cat# 48-GLUHU-
E01) from ALPCO Diagnostics (Salem, New Hampshire), respec-
tively. The manufacturer’s protocols were followed for both assays.
Quantification of islet cells and statistical analysis
Following immunofluorescence staining of the islets and nuclei,
the numbers of different cell types (a-, b-, d-, BrdU
+, Ki67
+) cells
and total islet cells in each islet were manually counted from the
islet microscopy images stored in Adobe Photoshop. Nuclear
staining was used to count the total cells in each islet. For each cell
type, 20–35 representative islets from 4–5 mice were counted. The
islets containing ,30 cells were excluded. All statistical analyses
were performed using GraphPad Prism biostatistics software
(GraphPad Software, Inc, La Jolla, California). The data were
expressed as Mean 6 SEM (standard error of the mean). P,0.05
was considered statistically significant.
Results
STZ-mediated b-cell destruction
Based on previous observations, we hypothesized that, similar to
the insulin-producing b-cells, non-b cells such as glucagon-
producing a-cells and somatostatin-producing d-cells in adults
could regenerate, and the regeneration could accelerate in the
event of b-cell loss. This study was thus designed to test this
hypothesis using a widely employed diabetes model whereby a
single-dose of STZ was used to achieve rapid b-cell destruction.
For the study, we first performed a dose response curve in C57BL/
6 mice (8–10 weeks old) via intraperitoneal (i. p.) injection with
doses ranging from 100 mg to 180 mg of STZ per kilogram body
weight (data not shown). We chose 130 mg of STZ per kilogram
body weight as the optimal dose for this study because it resulted in
hyperglycemia (blood glucose .300 mg/dL) in the mice within 2
days post injection, and allowed the mice to survive for
approximately 2 weeks without any treatment.
At select days after STZ treatment, the mouse pancreases were
harvested and processed for immunohistochemical staining. Anti-
insulin fluorescence staining of the pancreas slices showed acute b-
cell loss within the first 24 hours post STZ injection (Fig. 1A). As
shown in the representative microscopic images at 6 hrs, 12 hrs,
and 24 hrs post injection, b-cells underwent necrosis, and lost their
clear nuclei and cytoplasmic compartments. The remaining b-cells
in the islets were evident but continued to decrease over the next
few days. Quantification of the b-cells in each islet section showed
b-cell number significantly decreased beyond Day 2 post-STZ
treatment (2 d, 4 d, 6 d, 8 d, and 10 d) (Fig. 1B and 1C). The b-
cell composition, which was calculated as the percentage of b-cells
over the total number of cells in each islet, was reduced from about
70% in normal islets to less than 20% after STZ treatment
(Table 1). In addition, the number of identifiable islets in each
pancreas slice also decreased following STZ treatment. In normal
mice, we could detect 6.5 islets/mm
2 pancreatic slice. The density
decreased to 4.3 islets/mm
2 at Day 2, 3.4 islets/mm
2 at Day 6,
and 2.3 islets/mm
2 at Day 8 post-STZ treatment. All of these data
were consistent with the development of hyperglycemia in the
STZ-treated mice (Fig. 1D). Also accordingly, the insulin levels in
the serum of STZ-treated mice were significantly reduced, being
about 10% of the normal level at Day 2 (2 d), and declining to less
than 5% by Day 8 (8 d) post injection (Fig. 1E). Taken together,
these characterizations confirmed STZ-mediated b-cell destruc-
tion and establishment of diabetes in the mice.
Rapid a-cell regeneration following STZ treatment
Next, we examined the distribution of a-cells in the pancreases
of STZ-treated mice. Triple immunofluorescence staining with
anti-insulin, anti-glucagon and a nuclear dye Hoechst 33342
showed that, in normal mouse islets, a-cells were localized at the
periphery/mantle zone and b-cells in the core of the islets, which is
consistent with previous observations [31,32]. Two days following
STZ injection, a-cells started to expand into the core area, and
dominated the islets by Day 6 (Fig. 2A). Quantification of the a-
cells in each islet section showed a rapid increase in a-cell numbers
following STZ treatment, which became significantly different
from normal islets by Day 4, and peaked at Day 6 (Fig. 2C and
2D). The mean a-cell number in each islet section was nearly
doubled at Day 4, and tripled at Day 6 compared to that in the
normal islets (Fig. 2D). The mean a-cell numbers per islet at Day 8
and Day 10 slightly decreased from the peak value, but were still
more than 2 times of that seen in normal islets. This may be
Table 1. Composition of a-, b- and d-cells in islets from normal and STZ-treated mice.
Groups
%o fa-cells in each
islet
Unpaired t-test vs
normal
%o fb-cells in each
islet
Unpaired t-test vs
normal
%o fd-cells in each
islet
Unpaired t-test vs
normal
Normal 15.660.8 — 68.362.0 — 7.660.9 —
2 d 25.361.8 p,0.0001 37.662.0 p,0.0001 11.361.3 p=0.027
4 d 36.762.3 p,0.0001 24.761.9 p,0.0001 16.561.6 p,0.0001
6 d 50.561.5 p,0.0001 17.961.3 p,0.0001 18.261.6 p,0.0001
8 d 44.861.9 p,0.0001 15.261.1 p,0.0001 19.561.8 p,0.0001
10 d 43.061.4 p,0.0001 18.761.3 p,0.0001 16.160.9 p,0.0001
The percentage of a-, b-a n dd-cells was calculated against total cells (marked by nuclei staining) in each islet. 20–35 representative islets were counted for each group.
The results were expressed as mean 6 SEM. Unpaired t-tests were performed to compare the significance of the differences from the normal control. p,0.05 is defined
as significantly different. (*: p,0.05, **: p,0.005, ***: p,0.0005).
doi:10.1371/journal.pone.0036675.t001
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levels at these points. The rapid a-cell expansion was confirmed
with 3 different glucagon antibodies that were from different
commercial sources (see methods). Furthermore, the a-cell
composition in each islet also changed accordingly (Table 1).
The normal mouse islets contain about 15% of a-cells. Six days
following STZ treatment, the a-cells constituted more than 50% of
each islet (Table 1). Taken together, the rapid increase of a-cells in
each remaining islet following STZ treatment argued for the
regeneration of a-cells.
Interestingly, although a-cell expansion started 2 days after STZ
treatment, the glucagon concentration in serum decreased at Day 2
before gradually increasing, and became much higher than normal
level by Day 6 (Fig. 2B). In a representative experiment, serum
glucagon level reached to about 2 times of normal at Day 6, and
more than 6 times at Day 8 (Fig. 2B). This is not surprising because
glucagon secretion is highly regulated—it is normally inhibited by
insulin, somatostatin and high blood glucose. During the first few
days following STZ treatment, serum glucagon levels were low
probablybecauseofthereleaseofalargeamountofinsulinfromthe
dead b-cells, and the higher-than normal blood glucose. Later on,
with the decrease of serum insulin concentration and increase of a-
cells, insulin could no longer efficiently suppress glucagon secretion,
thus serum glucagon levels were high even in the presence of
hyperglycemia. In fact, the elevated glucagon levels could have also
contributedtothedevelopmentofhyperglycemiaasitisknownthat
glucagon stimulates glucose production from the liver.
Expansion of d-cells and PP cells following STZ treatment
We further investigated whether other non-b cells in the
pancreatic islets of adult mice regenerated following STZ-
mediated b-cell destruction. We first examined the distribution
of somatostatin-producing d-cells in the remaining islets of STZ-
treated mice. Mouse islets normally contain 5–10% d-cells which
Figure 2. a-cell expansion following STZ-mediated b-cell destruction. A: Immunofluorescence staining showing a-cell expansion following
STZ treatment. The pancreatic islets from normal and STZ-treated mice were co-stained with anti-Insulin (green) and anti-glucagon (red) antibodies.
Hoechst 33342 was used to label nuclei (blue). B: Glucagon levels in the serum of normal and STZ-treated mice. C: Quantitative distribution of a-cells
in each islet section. The number of a-cells in each islet was counted and plotted in the same way as described in Fig. 1B. 22–34 representative islets
from 4–5 mice were counted. The red line marks the mean value for each group. D: the statistical summary of a-cell distribution in islets from normal
mice and STZ-treated mice. *** indicates p,0.001; ns: not significant.
doi:10.1371/journal.pone.0036675.g002
Adult Non-b Islet Cell Regeneration
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36675are localized to the islet periphery (Table 1). After a single
diabetes-inducing dose of STZ, the distribution of d-cells changed
within days, and gradually became more centrally localized
(Fig. 3A). Quantitative analysis showed d-cell composition in the
remaining islets also increased. The average number of d-cells in
each islet doubled by Day 6 compared to that in normal mouse
islets (Fig. 3B and 3C), and constituted about 20% of the total cells
in each islet (Table 1). These data thus also support the
regeneration of d-cells in the adult mice following STZ treatment.
Co-staining of -cells and d-cells suggested the two cell types
followed a very similar pattern of expansion, although there were
more a-cells than d-cells in the remaining islets (Fig. 3A).
Figure 3. The distribution of a-cells and d-cells following STZ treatment. The pancreatic islets from normal and STZ-treated mice were co-
stained with anti-glucagon (green) and anti-somatostatin (red) antibodies. A: representative images showing d-cells expanded in a similar pattern to
a-cells following STZ treatment. B: Quantitative distribution of d-cells in each islet group. The quantification of d-cells was obtained the same way as
described for a-cells and b-cells in Figures 1 and 2. The redlines represent the mean values for each islet group. C: the statistical summary of d-cell
distribution in islets from normal mice and STZ-treated mice. The mark ** indicates p,0.005, and *** indicates p,0.0005; ns: not significant.
doi:10.1371/journal.pone.0036675.g003
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pancreatic polypeptide (PPP), and constitute less than 5% of all
islet cells in normal mice. Some PPP
+ cells also express glucagon
(Fig. 4B). Following STZ treatment, an increasing presence of
PPP
+ cells was observed in the islets over time, arguing for the
regeneration of PP cells. Interestingly, most PPP
+ cells were also
glucagon positive (Fig. 4B). This phenomenon did not appear to be
due to antibody cross-reaction because there were many
individually stained PP-cells and a-cells. The nature of the
PPP
+/Glucagon
+ bi-hormonal cells remains to be further inves-
tigated. Nonetheless, it is safe to say they represent a different
population of islet cells from the unihormonal a-cells or PP-cells.
Presence of these bi-hormonal cells complicated the quantification
of PP-cells and thus was not performed.
The spatial distribution of a-cells, d-cells and PP cells changed
dramatically following STZ-induced b-cell loss. To gain a more
clear insight into the islet cytoarchitecture, we performed triple
immunofluorescence staining using select islet cell markers. The
staining of a-, b-, and d-cells showed a clear change in islet
cytoarchitecture, with a loss in the core-to-mantle organization that
was seen in normal mouse islets. The non-b cells extended from the
periphery into the core, and became intermingled with the
remaining b-cells throughout the islets (Fig. 4A). Triple labeling of
a-, b-, and PP-cells revealed a similar cytoarchitecture change
(Fig. 4B).
BrdU incorporation suggests cell proliferation is involved
in a- and d-cell regeneration
Rapid expansion of a-cells and d-cells indicate that robust
regeneration of non-b cells was induced after STZ-mediated b-cell
destruction. Previous studies have demonstrated self-duplication,
regeneration from precursor cells or trans-differentiation from
other cells can all contribute to b-cell regeneration. Among these,
both self-duplication and regeneration from precursor cells involve
cell proliferation. To gain some insight into the mechanisms of
non-b-cells regeneration, we first examined whether proliferation
occurred during a- and d-cell expansion using an in vivo BrdU
incorporation assay. BrdU is a thymidine analogue that can be
incorporated into the genome during DNA replication, and has
been widely used as a marker for cell proliferation. In these
experiments, the mice were provided with 1 mg/ml BrdU-
containing drinking water immediately following STZ treatment.
At different day post-STZ, the pancreases were harvested and
subjected to immunohistochemical evaluation with an anti-BrdU
antibody and islet cell markers.
As shown in Fig. 5, in normal mice that were not treated by
STZ, BrdU
+ cells were detected in the core of the islets, which
were composed of mainly b-cells. This is consistent with previous
studies about b-cell regeneration [12,21,33]. Interestingly, we also
detected BrdU
+ a-cells and d-cells in normal mice, although at
very low frequency. This indicates, similar to b-cells, a-cells and d-
cells could also regenerate under normal physiological conditions
(Fig. 5A and 5C). Following STZ treatment, a-cells and d-cells
expanded into the core of the islets. We could readily detect BrdU
+
a-cells and BrdU
+ d-cells at each time point. Quantification of the
percentage of BrdU
+ a-cells (Fig. 5B) and d-cells (Fig. 5D) showed
STZ treatment significantly increased the proliferation of these
non-b cells, supporting that proliferation was involved in the
regeneration of these cells. It should be noted that a significant
number of a-cells and d-cells, including those that extended into
the core area of the islets, were not labeled by BrdU. This could be
explained by inefficient BrdU incorporation and/or failure of
immunohistochemical staining, but did not rule out the possibility
that these cells might have originated from non-proliferative
mechanisms such as trans-differentiation of existing islet cells.
Ki67 staining of proliferating cells argues for a role for
self-duplication in the regeneration of a- and d-cells
Since cell proliferation was involved in the non-b cell
regeneration, next we examined whether self-duplication could
Figure 4. Islet architectural changes following STZ-mediated b-cell loss and non-b cell regeneration. A: Distribution of a-, b- and d-cells
as assessed by triple staining with anti-insulin (blue), anti-glucagon (green) and anti-somatostatin (red) antibodies. The three cell types gradually lost
their normal mantle-to-core zone organization, and became intermingled throughout the islets. B: Distribution of a-, b- and PP cells as assessed by
anti-insulin (blue), anti-glucagon (green)) and anti-PPP (red) antibodies. Note: most regenerated PPP
+ cells appeared to co-express glucagon (white
arrows) following STZ treatment. This did not seem to be attributable to antibody cross-reaction because there were many individually stained a-cells
and PP-cells (pink arrows).
doi:10.1371/journal.pone.0036675.g004
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stained the islet cells with Ki67, a marker for proliferating cells.
Ki67 is expressed during the replicative phases of the cell cycle,
and is thus an excellent marker for cells that are dividing. This is
different from BrdU labeling because BrdU labels all cells that
have undergone DNA replication and thus is an accumulative
marker for cell proliferation. As shown in Fig. 6, at different days
post-STZ treatment, we detected Ki67
+ a-cells and d-cells, which
means these cells were in active replication. Quantitative analysis
showed the percentage of replicating a-cells in STZ treated mice
significantly increased compared to normal control, with the
highest value achieved at Day 6 post-STZ (Fig. 6B). Similar
observation was made for d-cells as well, although the differences
in the percentage of Ki67
+ d-cells were only significant at Day 4
and Day 6 post-STZ from normal control (Fig. 6D). Taken
together, these data suggest a-cells and d-cells could replicate,
and self-duplication was one of the mechanisms for their
regeneration following STZ treatment. Of note, similar to that
found with the BrdU incorporation assay, the number of
proliferating cells was far fewer than anticipated, especially
compared to the robust regeneration observed. This may be
attributable to poor antibody staining efficiency as the anti-Ki67
antibody was generated against human Ki67, and might not be
efficient in detecting mouse Ki67. Nonetheless, the presence of
proliferating a- and d-cells argues for self-duplication as one of
the mechanisms for their regeneration.
Pdx1 staining indicates endocrine progenitor cells play a
role in the regeneration of non-b cells
Endocrine progenitor cells have been shown to play a role in the
regeneration of b-cells [22,23]. To examine whether they were
involved in the regeneration of a- and d-cells, we co-stained the
pancreatic islet cells with Pdx1 antibody. The transcription factor
Pdx1 plays a critical role in embryonic pancreas development,
endocrine cell differentiation, and in maintaining mature b-cell
function [34,35,36,37,38]. It is expressed in developing pancreatic
precursor cells, and later becomes restricted to mature b-cells. Co-
staining of Pdx1 and insulin showed Pdx1 was expressed in the b-
cells of normal islets (Fig. 7A). In STZ-treated mice, Pdx1
expression diminished with b-cell loss, but subsequently, Pdx1
became readily detectable in more and more non-b cells (Fig. 7A).
Since Pdx1 is a marker for b-cells or pancreatic progenitor cells,
the Pdx1
+/Ins
2 cells represent the multipotent progenitor cells.
The increasing presence of these cells suggests they regenerated
following STZ treatment, and thus could play a role in the
regeneration of the non-b cells.
Figure 5. BrdU incorporation demonstrating that cell proliferation was involved in non-b-cell regeneration. Following STZ injection,
1 mg/ml of BrdU was added into the mice’s drinking water. Normal mice were included as the control. At different day post-STZ, the pancreases were
processed for immunofluorescence staining with anti-BrdU (red, A and C) and anti-glucagon (green, A) or anti-somatostatin (green, C). The arrows
mark BrdU
+ a-cells (A) and BrdU
+ d-cells (C) in the representative islets. The percentage of BrdU
+ a-cells (B) and BrdU
+ d-cells (D) were calculated by
dividing the number of these cells by total a- and d-cells in each islet, respectively. Unpaired t-tests were performed to compare whether the
percentage at each time point following STZ treatment was significantly different from that in normal mice. *: p,0.05, **: p,0.005, ***: p,0.0005, #:
p.0.05 (not significant).
doi:10.1371/journal.pone.0036675.g005
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regeneration of the non-b cells, we attempted to detect the cells
that were in the transition process from progenitor cells to mature
a-cell or d-cells. Normally Pdx1 expression is not detected in
mature a-o rd-cells. During transition from progenitor cells to a-
or d-cells, Pdx1 expression diminishes while glucagon or somato-
statin expression turns on. Co-staining of the islets using Pdx1 and
glucagon or somatostatin antibodies revealed the presence of
Pdx1
+/Glucagon
+ and Pdx1
+/somatostatin
+ cells following STZ
treatment (Fig. 7B and 7C), suggesting these cells were transition-
ing into mature a-o rd-cells. Taken together, these results suggest
endocrine progenitor cells played a role in the regeneration of the
non-b cells.
Discussion
In this study, we characterized the dynamic change of endocrine
cellcompositionofpancreaticisletsinadultmicethatwererendered
diabetic with a single dose of STZ. Our data suggested there was a
rapidandrobusta-andd-cellexpansionfollowingSTZ-mediatedb-
cell destruction, supporting our hypothesis that adult non-b
endocrine cells could be regenerated. We further sought to define
the mechanisms, specifically the cellular sources, of their regener-
ation. Our results demonstrated both self-duplication and regener-
ation from progenitor cells played a role in this process.
Regeneration of a-cells in adult mice has been observed in mice
whose b-cells were destroyed by toxins such as diphtheria toxin
(DT) and multiple low-doses of STZ [24,26]. Together with our
discovery, these studies have confirmed that a-cell regeneration
can be triggered by b-cell loss, the key characteristic of type 1
diabetes in animal models and in human patients. Indeed,
previous studies have shown a-cell composition increases in
human type 1 diabetic patients and in type 2 diabetic patients with
reduced number of b-cells [28,29,30,39,40], supporting a-cell
regeneration having occurred in these patients. How b-cell loss
triggers non-b cell regeneration, however, is not clear. Interest-
ingly, a recent study by Liu et al. has shown both insulin and
glucagon promotes a-cell proliferation in a-cell culture [29].
Whether this is true in vivo remains to be investigated.
Other novel discoveries made in this study include the
regeneration of d-cells and PP-cells. Our study demonstrated that,
similar to a- and b-cells, adult d-cells could also regenerate rapidly
under certain circumstances. In fact, our data on the mechanisms
of a- and d-cell regeneration indicate these specialized endocrine
cells share similar mechanisms for regeneration. Although we did
not quantify the expansion of PP-cells due to bi-hormonal staining
Figure 6. Ki67 staining highlighted proliferating a-cells and d-cells. A and C: double staining of the islets with the proliferating cell marker
Ki67 (red) with anti-glucagon (green, A) or with anti-somatostatin (green, C). The white arrows mark the proliferating a-cells and d-cells, respectively.
B and D: the percentage of Ki67
+ a-cells/total a-cells (B) and Ki67
+ d-cells/total d-cells (D) in each islet was quantified. Unpaired t-tests were performed
to compare whether the data at each time point post-STZ was significantly different from that in normal mice. *: p,0.05, **: p,0.005, #: p.0.05 (not
significant).
doi:10.1371/journal.pone.0036675.g006
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nature of the bi-hormonal cells remains to be determined. One
plausible explanation is they represent certain intermediate/
precursor cells.
Over the past few years, significant progress has been made with
regard to the regeneration of b-cells in adults. It has been
demonstrated that b-cells can be regenerated by self-duplication,
from progenitor cells or by trans-differentiation of a-cells
[19,20,21,22,23,24]. Mechanisms of non-b cell regeneration,
however, have not been reported. In our initial search of the
mechanismsfora-cellandd-cellregeneration,wefirstexaminedcell
proliferation, which underlines two of the mechanisms of b-cell
regeneration: self-duplication and regeneration from progenitor
cells. Our BrdU incorporation assays confirmed cell proliferation
playedaroleina-andd-cellregenerationfollowingSTZtreatment.
Nonetheless, the number of BrdU
+ cells fell short compared to the
massive increase of a- and d-cells. Inefficient incorporation or
staining defects may have accounted for the observed results. To
exclude the possibility in regards to imminohistochemical staining,
we performed the assays under different conditions and with
different antibodies, and repeated the experiments many times. All
showed similar results. In addition, the positive staining was very
clean and clear (Fig. 5), suggesting that staining was not the issue.
The BrdU concentration used in this study was similar to what has
beenreported inthe literature[21,33,41],thusitwasexpected tobe
sufficient to label most, if not all, proliferating cells. It is possible,
however, that the proliferation happened so rapidly that the
concentration of BrdU was not sufficient for all of the proliferating
cells to incorporate it into their replicating DNA. Another plausible
explanationisthisinabilitytolabelmostnewlyformeda-andd-cells
simply mean mechanisms that do not involve proliferation played a
part in their regeneration.
Although the number of BrdU
+ cells was less than expected, our
data demonstrated the participation of cell proliferation in the
regeneration of a- and d-cells. Furthermore, Ki67 labeling of
proliferatingcellsshowedbotha-cellsandd-cellshadthecapacityof
self-duplication, similar to b-cells [19,20,21]. Self-duplication is
believed to be the major mechanism for normal b-cell turnover
under physiological conditions. Our data suggest a- and d-cells in
adults may adopt the same mechanism for normal tissue replenish-
ment.Self-duplicationoccurredinthediabetesmodelsinducedbya
single-dose of STZ. However, the sparseness of Ki67
+ a-cells or d-
cells, in contrast to their rapid and robust regeneration, indicates
Figure 7. Pdx1 expression in STZ-treated mouse islets. The pancreatic islets from normal and STZ-treated mice were co-stained with anti-Pdx1
(red in A, B, and C) and islet cell markers including anti-insulin (A, green), anti-glucagon (B, green) and anti-somatostatin (C, green). In the normal
islets, Pdx1 co-localized with insulin-expressing b-cells. Following STZ-mediated b-cell destruction, Pdx1 expression diminished, but became
detectable in more and more non-b cells (A, arrows). Co-staining of Pdx1 with glucagon or somatostatin antibodies showed presence of Pdx1
+/
glucagon
+ (B, arrows) and Pdx1
+/somatostatin
+ (C, arrows) cells following STZ-treatment, suggesting these cells are multipotent progenitor cells in
transition to a- and d-cells respectively.
doi:10.1371/journal.pone.0036675.g007
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following STZ-mediated acute b-cell destruction.
The transcription factor Pdx1 is expressed in developing
endocrine cells during mouse embryogenesis and in mature
insulin-producing b-cells [42]. b-cell specific inactivation of the
transcription factor Pdx1 resulted in b-cell loss and a-cell
expansion [34,35]. Our examination of Pdx1 expression showed
a diminishing of Pdx1 in b-cells, and an emergence of Pdx1
+ non-
b cells (Pdx1
+/Ins
2) following STZ treatment. These Pdx1
+/Ins
2
cells appeared to be multipotent endocrine progenitor cells which
have the capacity to differentiate into a-, d- and b-cells, mimicking
embryonic endocrine cell development. Indeed, we were able to
detect Pdx1
+/glucagon
+ and Pdx1
+/somatostatin
+ cells following
STZ treatment, suggesting these cells were in the transition process
into mature a- and d-cells, respectively. Due to the transient
nature of the transition, it is not unexpected that most of the
glucagon
+ and somatostatin
+ cells were not Pdx1
+. Taken
together, our data demonstrate that endocrine progenitor cells
play a role in the regeneration of a- and d-cells. This is consistent
with previous studies that have shown progenitor cells are present
in adult mouse islets, and can serve as the cellular origins for b-cell
regeneration [22,23].
Another interesting discovery is, a-cell regeneration in our
single dose model (130 mg STZ per kilogram bodyweight)
occurred at a much more rapid pace compared to that in the
multiple low dose STZ model (40 mg STZ per kilogram
bodyweight daily for 5 days) [26]. In the single high dose model,
significant a-cell regeneration was detected at Day 2 and peaked at
Day 6 post-STZ. In contrast, an increase in a-cell composition was
detected at Day 14, and did not reach the highest value until Day
21 in the multiple low-dose model [26]. This pace appears to
correlate with the rate of b-cell loss and diabetes development in
the two different STZ models— hyperglycemia develops by Day 2
for the single high dose model (Fig. 1), but it took 7 days in the
multiple-low dose model [26].
Despite the rapid increase of a-cells in the STZ-treated mice,
serum glucagon levels did not completely correlate with the
number of a-cells. Glucagon levels decreased at first, and then
gradually rose. This was not unexpected as hormonal secretion in
the endocrine cells is known to be highly regulated. Normally,
glucagon is secreted in response to low blood glucose, and is also
regulated by serum insulin and somatostatin [13,14,15,17,18]. The
serum glucagon levels were lower in STZ-treated mice, probably
because of a higher blood-glucose than in normal mice. However,
with the disturbances in insulin secretion and loss of normal cell-
cell communication that resulted from b-cell loss [13], and a- and
d-cell expansion, glucagon secretion was no longer tightly
regulated. Therefore, with an increasing presence of a-cells from
Day 2 to Day 8, glucagon secretion increased despite the higher
blood glucose in these STZ-treated mice.
It is noteworthy that a-cell hyperplasia has also been observed
in neonatal rats following STZ treatment [43]. Similar to our
study, a-cell and d-cell composition increased during the first few
days in the neonatal rats following a single diabetes-inducing dose
of STZ. However, there are clear differences between neonatal
and adult animals. For example, the neonatal rats developed
hyperglycemia two days post- STZ treatment, but returned to
near-normal level after 20 days [43,44]. In contrast, the adult mice
in our study could only survive two weeks without insulin
treatment. In the neonatal rats, the islet architecture appeared to
be normal with a dense b-cell core at Day 20 [43], while the islet
cells in adults became intermingled following STZ treatment
(Fig. 4). The differences are not surprising because neonatal
pancreas undergoes substantial remodeling [7,8,9]. At this stage,
b-cell apoptosis, replication, and neogenesis happen rapidly, and
thus STZ-induced b-cell loss can be compensated.
In summary, our study has revealed that glucagon-producing a-
cells and somatostatin-producing d-cells can rapidly regenerate
following a single diabetes-inducing dose of STZ treatment in
adult mice. Both self-duplication and regeneration from intra-islet
progenitor cells play a role in their regeneration. Our data,
however, did not exclude non-proliferative mechanisms in the
regeneration of the non-b cells.
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